Iambic Therapeutics, based in San Diego, redefines drug discovery by combining human ingenuity with the power of AI. Emphasizing AI-driven design and automation, the company is a pioneer in creating data-efficient, physics-informed AI models. Iambic Therapeutics achieves more reliable and accurate modeling by incorporating physics principles into AI architectures, enabling deeper exploration in chemical space and accelerating the journey toward innovative medical solutions.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
06/18/2024 | Series B-2 | $50MM | $xx.xx | $382.7MM | Mubadala Capital, Exor Ventures, Qatar Investment Authority, Abingworth, Illumina Ventures, Nexus Venture Partners, Coatue, Tao Capital Partners | |
Price per Share
$xx.xx
Shares Outstanding
16,828,217
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Mubadala Capital, Exor Ventures, Qatar Investment Authority, Abingworth, Illumina Ventures, Nexus Venture Partners, Coatue, Tao Capital Partners
|
||||||
10/03/2023 | Series B | $106.23MM | $xx.xx | $275.56MM | Ascenta Capital, Abingworth, NVIDIA, Illumina Ventures, Gradiant Corporatoin, Shanda, Nexus Ventures, Catalio Capital Management, Coatue, FreeFlow, OrbiMed, Sequoia Capital, Tao Capital | |
Price per Share
$xx.xx
Shares Outstanding
42,904,185
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Ascenta Capital, Abingworth, NVIDIA, Illumina Ventures, Gradiant Corporatoin, Shanda, Nexus Ventures, Catalio Capital Management, Coatue, FreeFlow, OrbiMed, Sequoia Capital, Tao Capital
|
||||||
07/14/2021 | Series A-1 | $2MM | $xx.xx | $173.61MM | Coatue, Catalio Capital Management, OrbiMed, Sequoia Capital, Nexus Venture Partners, FreeFlow | |
Price per Share
$xx.xx
Shares Outstanding
1,053,462
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Coatue, Catalio Capital Management, OrbiMed, Sequoia Capital, Nexus Venture Partners, FreeFlow
|
||||||
07/14/2021 | Series A | $67.15MM | $xx.xx | $173.61MM | Coatue, Catalio Capital Management, OrbiMed, Sequoia Capital, Nexus Venture Partners, FreeFlow | |
Price per Share
$xx.xx
Shares Outstanding
28,295,040
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Coatue, Catalio Capital Management, OrbiMed, Sequoia Capital, Nexus Venture Partners, FreeFlow
|
||||||
04/01/2020 | Series Seed | $2.52MM | $xx.xx | $8.4MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
7,231,110
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|